Mr. Dwight Gorham reports

INTELGENX PROVIDES RIZAFILM(TM) U.S. COMMERCIALIZATION UPDATE

IntelGenx Corp. has received the first purchase order (PO) for RizaFilm from its commercial partner in the United States, Gensco Pharma.

The PO triggers an upfront order deposit payment. A prespecified milestone payment to IntelGenx from Gensco is also payable upon transfer of NDA. Both payments will be reflected in the company's Q3 2023 financial results. IntelGenx expects to ship the ordered RizaFilm product to Gensco in Q1 2024 for immediate launch.

"We have been impressed with the progress Gensco has made, and remain convinced that it is the right partner to help us bring this innovative migraine therapeutic to U.S. patients seeking convenient administration and quick pain relief," commented Dwight Gorham, IntelGenx's chief executive officer. "We are also pleased that our balance sheet will be strengthened in the current quarter by the deposit and milestone payments triggered by Gensco's PO for RizaFilm."

Gensco's chairman and CEO, Dr. Paul Zimmerman, MD, commented: "Our team has been working closely with its talented colleagues at IntelGenx to lay the groundwork for what we believe will be a very successful commercial launch of RizaFilm, the first oral thin film approved for the treatment of acute migraines in the U.S. Beyond that, we continue to look forward to building a successful long-term partnership with IntelGenx."

About RizaFilm

RizaFilm (U.S. market name for Rizaport) is a proprietary oral thin film formulation of rizatriptan benzoate. RizaFilm oral soluble film does not require a drink for swallowing and has ease of use which facilitates rapid administration and relief from migraine symptoms. RizaFilm's active ingredient has been clinically proven to be effective for migraine-associated nausea, photophobia and phonophobia. The global migraine drugs market was valued at nearly $3-billion in 2021 and is expected to reach nearly $11-billion by 2030, representing a compound annual growth rate of 15.6 per cent. According to the American Migraine Foundation, 39 million or 12 per cent of Americans suffer from migraine, which is the second leading cause of disability nationwide.

About IntelGenx Corp.

IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.

IntelGenx's superior film technologies, including VersaFilm, DisinteQ, VetaFilm and transdermal VevaDerm, allow for next-generation pharmaceutical products that address unmet medical needs. IntelGenx's innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions.

IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including research and development, analytical method development, clinical monitoring, intellectual property, and regulatory services. IntelGenx's state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production, as well as other CDMO (contract development and manufacturing organization) services.

We seek Safe Harbor.